News

The therapies include Onbrez Inhalation Capsules 150 mcg (indacaterol maleate) and the investigational drugs NVA237 (glycopyrronium bromide) and QVA149 (fixed-dose combination of indacaterol maleate and glycopyrronium bromide). NVA237and

The move indicates that in patients with unknown or negative Rearranged during Transfection (RET) mutation, a lower benefit should be considered prior to individual treatment decisions. Clinical data

MM-121 is a fully human monoclonal antibody that targets ErbB3, while erlotinib (Tarceva) is a small molecule directed at the epidermal growth factor receptor (EGFR). The study is

Sativex is also protected by a number of other patents related to different aspects of the product. GW chairman Geoffrey Guy said the grant of this patent is

Vitera’s solutions are believed to improve practice management and improve patient care which is why facilities from Connecticut, Florida, Kentucky, Nevada, Pennsylvania and Texas have adopted the Vitera

Under the partnership agreement, both the companies are delving into the technical details of the integration which will result into integration between the OnCore system for clinical research

As part $2m fund, Susan has granted $450,000 to a team led by Lisa Gallicchio at Mercy Medical Center to study why African American breast cancer patients may

In exchange for rights to jointly co-develop and co- market the products, Shionogi will pay a one time fee and share costs to Shire. Shire ADHD business senior

IDRI research lays emphasis on identifying new therapies to fight tuberculosis (TB), including multidrug-resistant TB (MDR-TB). The additional funding through Eli Lilly to support early stage TB drug